Hepatitis C
Conditions
Keywords
Healthy volunteers
Brief summary
This is a healthy volunteer study looking at the interactions between two drugs: boceprevir and sildenafil. New drugs are being developed to treat people with the chronic viral infection hepatitis C. Very little is know how these new treatments interact with other medications such as the drugs used to treat erectile dysfunction. The purpose of this study is to look at levels of both a new hepatitis C drug called boceprevir (BOC) and an existing erectile dysfunction drug called sildenafil to see if they affect the blood levels of each other when given separately and together.
Detailed description
Total duration for each participant will be up to 40 days plus a screening visit 1 - 3 weeks prior to the start of the study. They will visit the clinic on 10 occasions: screening visit, baseline visit (day 0), day 1, a visit between day 4 and 7, day 10, day 14, day 15, day 16, day 17 and a follow up visit between days 26 and 40. The total amount of blood collected from participants during the entire study will be no greater than 350 ml in total (around 23 tablespoons). At the screening visit a clinical assessment will be performed. At the baseline visit participants will attend the clinic fasted and will be required to remain on the unit for approximately 14 hours. On the morning of the visit clinical assessments will be performed. Sildenafil 25mg (1 tablet) will be administered with a standardised meal. Blood samples will be taken at the following times in order to measure the levels of sildenafil in the blood: predose,0.5, 1, 2, 3, 4, 6, 8, 10,12 and 24 hours post dose. On day Day 10 boceprevir will be initiated 800mg (4 capsules 3 times a day) for the next 4 days on day 14 the participants will attend the clinic for a witnessed dose of boceprevir and safety assessment. On day 15 the participants will attend for their 2nd long visit (10 hours) when they will be administered boceprevir (BOC) 800mg (4 capsules) with a standardised meal then have blood samples taken at the following times in order to measure the levels of BOC in the blood: predose,0.5, 1, 2, 3, 4, 6 and 8 hours post dose. After the 8 hour blood collection participants will be administered boceprevir (BOC) 800mg (4 capsules) with food and they will self administer BOC 800mg (4 capsules) with food at home 8 hours later. On day 16 participants will attend for the 3rd long visit (14 hours) where they will be administered boceprevir (BOC) 800mg (4 capsules) and sildenafil 25mg with a standardised meal. Blood samples will be taken at the following times in order to measure the levels of both BOC and sildenafil in the blood: predose,0.5, 1, 2, 3, 4, 6 and 8 hours post dose. After the 8 hour blood collection participants will be administered boceprevir (BOC) 800mg (4 capsules) with food and will then self administer BOC 800mg (4 capsules) with food at home 8 hours later. This will be their last dose of study medication. They will return the next day for a final blood test post 24 hours. A final visit between days 26 and 40 will be performed including clinical assessments.
Interventions
DRUGSildenafil and Boceprevir
25mg once/800mg three times a day
Sponsors
Imperial College London
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
* The ability to understand and sign a written informed consent form, prior to participation in any screening procedures and must be willing to comply with all study requirements. * Subjects in good health upon medical history, physical exam, and laboratory testing and BMI \<32. * Subjects who are heterosexually active must use two forms of barrier contraception (e.g., condom with spermicide) during heterosexual intercourse, from screening through completion of the study including 10 days following last dose of study drug. * Have no serologic evidence of HIV or HCV infection through antibody testing at screening. * Have screening laboratory results (haematology, chemistry) that fall within the normal range of the central laboratory's reference ranges unless the results have been determined by the Investigator to have no clinical relevance
Exclusion criteria
* Any serious or active medical or psychiatric illness which, in the opinion of the Investigator, would interfere with subject treatment, assessment, or compliance with the protocol. This would include any active clinically significant renal, cardiac, hepatic, pulmonary, vascular, metabolic (thyroid disorders, adrenal disease), immunodeficiency disorders, active infection, or malignancy. * Previous participation in an investigational trial involving administration of any investigational compound within 1 month prior to the study screening. * Clinically relevant alcohol or drug use (positive drug screen) or history of alcohol or drug use considered by the Investigator to be sufficient to hinder compliance with treatment, follow-up procedures or evaluation of adverse events. Smoking is permitted, but tobacco intake should remain consistent throughout the study. * Any medication taken listed in protocol including over-the-counter medications and herbal products within 21 days of commencing study drug dosing with the exception of vitamins and/or paracetamol. When a concomitant medication is necessary, this will be reviewed by the Investigator and if not contraindicated, may be continued at the same dose and frequency during the study period. * History of drug sensitivity or drug allergy which in the opinion of the investigator may put the subject at increased risk of drug reactions during the study. * Subjects with female partners who are pregnant will not be allowed to enter the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Sildenafil Alone Maximum Plasma Concentration | Day 1 | Single dose sildenafil 25mg will be administered with food. Intensive pharmacokinetic sampling will be taken over a 24 hour period (0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 and 24 hours post dose) |
| Boceprevir Alone Maximum Plasma Concentration | day 10-15 | Day 10 commence BOC 800mg three times a day with food. On day 15 at steady state, subjects will attend for witnessed dosing and an intensive pharmacokinetic visit over 8 hours (samples drawn 0, 0.5, 1, 2, 3, 4, 6 and 8 hours post dose) |
| Sildenafil Maximum Plasma Concentration | Day 16 | administer BOC 800mg and single dose sildenafil 25mg with food. Intensive pharmacokinetic sampling will be taken over a 24 hour period (0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 and 24 hours post dose) |
| Boceprevir Maximum Plasma Concentration | Day 16 | administer BOC 800mg and single dose sildenafil 25mg with food. Intensive pharmacokinetic sampling will be taken over a 24 hour period (0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 and 24 hours post dose) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Patients With Adverse Events | Day 1 - 16 | The number of repeated adverse events will be used to assess the safety of the drugs in combination |
Countries
United Kingdom
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Sildenafil and Boceprevir All subjects take single dose sildenafil 25mg day 0, day 10-15 they take boceprevir 800mg three times a day followed by Intentive PK on day 15 and on day 16 single dose of sildenafil and boceprevir together followed by intensive PK | 13 |
| Total | 13 |
Baseline characteristics
| Characteristic | Sildenafil and Boceprevir |
|---|---|
| Age, Continuous | 36 years |
| Body Mass Index | 26.2 kg/m2 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 4 Participants |
| Race (NIH/OMB) Black or African American | 3 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 6 Participants |
| Sex: Female, Male Female | 0 Participants |
| Sex: Female, Male Male | 13 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 0 / 13 |
| serious Total, serious adverse events | 0 / 13 |
Outcome results
Primary
Boceprevir Alone Maximum Plasma Concentration
Day 10 commence BOC 800mg three times a day with food. On day 15 at steady state, subjects will attend for witnessed dosing and an intensive pharmacokinetic visit over 8 hours (samples drawn 0, 0.5, 1, 2, 3, 4, 6 and 8 hours post dose)
Time frame: day 10-15
| Arm | Measure | Value (GEOMETRIC_MEAN) |
|---|---|---|
| Sildenafil Only | Boceprevir Alone Maximum Plasma Concentration | 1432.5 ng/mL |
Primary
Boceprevir Maximum Plasma Concentration
administer BOC 800mg and single dose sildenafil 25mg with food. Intensive pharmacokinetic sampling will be taken over a 24 hour period (0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 and 24 hours post dose)
Time frame: Day 16
| Arm | Measure | Value (GEOMETRIC_MEAN) |
|---|---|---|
| Sildenafil Only | Boceprevir Maximum Plasma Concentration | 1440.5 ng/mL |
Primary
Sildenafil Alone Maximum Plasma Concentration
Single dose sildenafil 25mg will be administered with food. Intensive pharmacokinetic sampling will be taken over a 24 hour period (0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 and 24 hours post dose)
Time frame: Day 1
| Arm | Measure | Value (GEOMETRIC_MEAN) |
|---|---|---|
| Sildenafil Only | Sildenafil Alone Maximum Plasma Concentration | 79.9 ng/mL |
Primary
Sildenafil Maximum Plasma Concentration
administer BOC 800mg and single dose sildenafil 25mg with food. Intensive pharmacokinetic sampling will be taken over a 24 hour period (0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 and 24 hours post dose)
Time frame: Day 16
| Arm | Measure | Value (GEOMETRIC_MEAN) |
|---|---|---|
| Sildenafil Only | Sildenafil Maximum Plasma Concentration | 150.9 ng/mL |
Secondary
Number of Patients With Adverse Events
The number of repeated adverse events will be used to assess the safety of the drugs in combination
Time frame: Day 1 - 16
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Sildenafil Only | Number of Patients With Adverse Events | 0 participants |